Alfasigma claims early FDA nod for ex-GSK liver drug Alfasigma has claimed the first approval, in the US, for linerixibat, a drug for liver disease PBC licensed from GSK for $690m a few days ago.

The #FDA has approved #Alfasigma's #primarybiliarycholangitis (PBC) therapy #linerixibat, just days after the company licensed it from #GSK in a deal worth up to $690 million.

pharmaphorum.com/news/alfasig...

#GSK has signed an eleventh-hour agreement to give #Alfasigma rights to its #primarybiliarycholangitis (PBC) therapy linerixibat, which is under #regulatoryreview in most major pharma markets #worldwide.

buff.ly/TotgbnR

The Adverse Impact of Poorly Controlled Pruritus Associated With PBC Research shows poorly controlled pruritus can result in extremely adverse quality-of-life outcomes, making symptomatic control a clinical priority.

#Pruritus is a hallmark symptom of primary biliary cholangitis (#PBC), yet its specific impact on quality of life is frequently overshadowed by broader disease metrics.

Learn more: https://bit.ly/3M5joNn

#RareDisease #PrimaryBiliaryCholangitis #MedSky

Study Uncovers Mechanism of How BaP Induces PBC BaP exerts its activity in the pathogenesis of primary biliary cholangitis (PBC) by targeting the Fc receptor-like 3 gene, a new study shows.

Benzo[a]pyrene (#BaP) exerts its activity in the pathogenesis of primary biliary cholangitis (#PBC) by targeting the Fc receptor-like 3 (#FCRL3) gene. Study in BMC Gastroenterology.

Read more: https://bit.ly/4bQtoEE

#RareDisease #PrimaryBiliaryCholangitis #Gastroenterology

Factors Associated With PBC May Vary by Geographic Location Bacterial infection may be associated with the development of autoimmune diseases like primary biliary cholangitis (PBC).

#BacterialInfection may be associated with the development of #AutoimmuneDiseases like #PrimaryBiliaryCholangitis (#PBC) through molecular mimicry between human and bacterial proteins. Study in @frontiersin.bsky.social in Cellular and Infection Microbiology.

Read more: https://bit.ly/4kjDxfc

Study Shows Recompensation Is Possible in PBC With Decompensated Cirrhosis A new study shows it is possible that patients with PBC and decompensated cirrhosis regress to a recompensated stage.

Patients with #PrimaryBiliaryCholangitis (#PBC) and decompensated cirrhosis may be able to regress to a recompensated stage. Study in the Journal of Gastroenterology.

Read more: https://bit.ly/3LF4UUd

#RareDisease #MedSky #Gastroenterology

The PBC Research Foundation: Turning Frustration Into a Data Revolt The PBC Research Foundation is building a dataset to connect communities across related conditions and break down diagnostic and systemic silos.

The PBC Research Foundation is building a dataset to connect communities across related conditions and break down diagnostic and systemic silos.

Read the feature by Sarah Mahoney ➡️: https://bit.ly/491FlEh

#RareAdvocacySpotlight #RareDisease #PBC #PrimaryBiliaryCholangitis #MedSky

Seladelpar’s Efficacy for PBC Demonstrated in a Real-World Clinical Setting The efficacy of seladelpar as a second-line therapy in patients with PBC has been demonstrated in a real-world clinical setting.

The efficacy of #Seladelpar as a second-line therapy in patients with primary biliary cholangitis (#PBC) has been demonstrated in a real-world clinical setting.

Read more: https://bit.ly/4pRad1g

#RareDisease #PrimaryBiliaryCholangitis

Linerixibat Significantly Reduces Pruritus in PBC The GLISTEN trial tested the safety, efficacy, and impact of linerixibat on patients’ health-related quality of life compared with a placebo.

#Linerixibat significantly reduces #Pruritus compared with placebo in patients with #PrimaryBiliaryCholangitis (PBC), according to results from the phase 3 clinical GLISTEN trial (#NCT04950127). Published in @lancetgastrohep.bsky.social

Read here: https://bit.ly/4oZ6tKk

#RareDisease #ClinicalTrial

Hyperlipidemia in PBC May Not Be So Benign After All Patients with PBC and hyperlipidemia had significantly higher rates of cardiovascular and metabolic outcomes.

#TLM25: Hyperlipidemia is associated with a significantly higher cardiovascular and metabolic disease burden in #PrimaryBiliaryCholangitis while also being linked with lower mortality and fewer liver complications. @aasldnews.bsky.social

Read here: https://bit.ly/47ADYNv

#RareDisease #PBC #MedSky

Researchers Identify New Mechanism of Inflammation and Fibrosis in PBC Bruton’s tyrosine kinase inhibition with evobrutinib attenuated inflammation in hepatocytes, macrophages, neutrophils, and activated stellate cells.

#TLM25: Bruton’s tyrosine kinase (#BTK) controls inflammation and #Fibrosis in primary biliary cholangitis (#PBC), found researchers from @bidmcreseach.bsky.social at @harvardmed.bsky.social in Boston, Massachusetts.

Read more: https://bit.ly/48286Br

#RareDisease #PrimaryBiliaryCholangitis

#TLM25: Aliya Gulamhusein, MD, hepatologist at the Toronto Centre for Liver Disease, speaking Nov. 8 at @aasldnews.bsky.social in Washington, D.C., on managing #PrimaryBiliaryCholangitis (PBC).

Image & quote taken by Senior Correspondent, Larry Luxner.

#RareDisease #Hepatology #PBC #MedSky

#TLM25: Cecilia Dueñas, PsyD, of San Diego, Calif., who was eventually diagnosed with #PrimaryBiliaryCholangitis (PBC) and went on to establish the PBC Research Foundation. Dr. Dueñas spoke Nov. 7 at the @aasldnews.bsky.social 2025

Image & quote taken by Senior Correspondent, Larry Luxner

#MedSky

Standardized Care for PBC-Associated Pruritus May Be Useful in All Settings The assessment and management of primary-biliary cholangitis (PBC)-associated pruritus differs by the level of healthcare, a study found.

#Pruritus is common among patients with primary biliary cholangitis (#PBC) and is under-treated, confirms a new study published in the scientific journal Annals of Hepatology.

Read more: https://bit.ly/4nTD0kT

#RareDisease #PrimaryBiliaryCholangitis #Hepatology

UPDATE 📢 Following our previous post about the national shortage of Rifampicin in the UK, PSC Support and @PBCFoundation have released a joint statement.
Also available to read on our website.
➡️ buff.ly/f4VFqpj
#LetsBeatPSC #PBC #PrimaryBiliaryCholangitis #Liver #PSCItch #PBCItch

EU kicks off review of GSK's linerixibat in PBC GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

The #EMA has started a review of #GSK's treatment candidate for #primarybiliarycholangitis, linerixibat, offering hope to patients of an effective treatment for the relentless #itching caused by the autoimmune #liverdisease.

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE The life-long condition affects approximately 1,900 people in Scotland

#hepatology #gastroenterology #Ipsen #Iqirvo #elafibranor #SMC #ScottishMedicinesConsortium #SMCapprovel #liverdisease #primarybiliarycholangitis #Scotland #NHSScotland #rarecholestaticliverdisease #NICE #NICErecommended #PBCpatients #ELATIVEtrial #cholestasis
pmlive.com/ipsens-iqirv...

Soluble Herpes Virus Entry Mediator and Type II/III Interferons Are Upregulated in Primary Biliary Cholangitis Bacterial translocation-induced inflammation and immune dysfunction are recognised factors contributing to the pathogenesis of primary biliary cholangitis (PBC). However, the specific involvement of i...

So happy to announce my first 1st-author publication, on immunological signatures of disease severity and response to #ursodeoxycholate (UDC) in #PrimaryBiliaryCholangitis (#PBC)

doi.org/10.3390/ijms26020605

@drantonioriva.bsky.social @inst-of-liver.bsky.social

MDADI MDADI

Learn about timely diagnosis of and treatment initiation for #PrimaryBiliaryCholangitis in order to slow disease progression, with Dr. Christopher L. Bowlus. Join us! bit.ly/49eEboL